Filing Flows › Zenas BioPharma (ZBIO) › R&D spending
Zenas BioPharma (ZBIO) R&D spending by quarter
Zenas BioPharma's R&D spending was $58.5M in Q3 2026 (third quarter 2026), -7% from Q2 2026. Over the last 4 quarters it ranged from $34.9M (Q1 2025) to $62.9M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $58.5M | -7% | — |
| Q2 2026 | $62.9M | +80% | — |
| Q1 2025 | $34.9M | -29% | — |
| Q4 2024 | $49.2M | — | — |
Q3 2026 at a glance
Zenas BioPharma, Q3 2026: revenue $10.0M, net loss $109M, operating cash flow −$58.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Zenas BioPharma's R&D spending?
Zenas BioPharma's R&D spending was $58.5M in Q3 2026 (third quarter 2026), -7% from Q2 2026.
How has Zenas BioPharma's R&D spending changed?
Over the last 4 quarters it ranged from $34.9M (Q1 2025) to $62.9M (Q2 2026).